Osiris Reports First Quarter 2014 Results: Revenue Up 25% and Gross Margin Improved from 73% to 78%

[Business Wire] – Osiris Therapeutics, Inc. , the leading stem cell company focused on developing and marketing products in wound care, orthopedic and sports medicine markets announced more

View todays social media effects on OSIR

View the latest stocks trending across Twitter. Click to view dashboard

See who Osiris is hiring next, click here to view